Eisai files for full FDA approval for Alzheimer’s drug Leqembi

Reuters

(Reuters) – Japanese drugmaker Eisai Co Ltd said on Saturday it had submitted an application to the U.S. Food and Drug Administration for a standard review of its Alzheimer’s drug Leqembi, which was recently approved under the agency’s accelerated review process.

(Reporting by Bhanvi Satija in Bengaluru; Editing by William Mallard)

Related News:   New Restaurant Joins Brick Township's Business Tax Relief Program

tagreuters.com2023binary_LYNXMPEJ06019-BASEIMAGE

You appear to be using an ad blocker

Shore News Network is a free website that does not use paywalls or charge for access to original, breaking news content. In order to provide this free service, we rely on advertisements. Please support our journalism by disabling your ad blocker for this website.